Does the media refer more to ALDX or SNDL?

In the previous week, Aldeyra Therapeutics had 2 more articles in the media than SNDL. MarketBeat recorded 7 mentions for Aldeyra Therapeutics and 5 mentions for SNDL. SNDL's average media sentiment score of 1.06 beat Aldeyra Therapeutics' score of 0.16 indicating that SNDL is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aldeyra Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SNDL 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CMPX or ALDX more profitable?

Compass Therapeutics' return on equity of -39.75% beat Aldeyra Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Compass Therapeutics N/A -39.75% -35.29% Aldeyra Therapeutics N/A -57.34% -36.33%

Does the media prefer CMPX or ALDX?

In the previous week, Aldeyra Therapeutics had 3 more articles in the media than Compass Therapeutics. MarketBeat recorded 7 mentions for Aldeyra Therapeutics and 4 mentions for Compass Therapeutics. Compass Therapeutics' average media sentiment score of 0.41 beat Aldeyra Therapeutics' score of 0.16 indicating that Compass Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compass Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aldeyra Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend PBYI or ALDX?

Aldeyra Therapeutics has a consensus price target of $5.50, suggesting a potential upside of 213.39%. Given Aldeyra Therapeutics' higher possible upside, analysts clearly believe Aldeyra Therapeutics is more favorable than Puma Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Puma Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Aldeyra Therapeutics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media prefer PBYI or ALDX?

In the previous week, Aldeyra Therapeutics had 6 more articles in the media than Puma Biotechnology. MarketBeat recorded 7 mentions for Aldeyra Therapeutics and 1 mentions for Puma Biotechnology. Puma Biotechnology's average media sentiment score of 0.94 beat Aldeyra Therapeutics' score of 0.16 indicating that Puma Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Puma Biotechnology 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aldeyra Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, ALDX or LRMR?

Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aldeyra Therapeutics N/A N/A -$33.85M -$0.46 N/A Larimar Therapeutics N/A N/A -$165.67M -$2.06 N/A

Is ALDX or LRMR more profitable?

Aldeyra Therapeutics' return on equity of -57.34% beat Larimar Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aldeyra Therapeutics N/A -57.34% -36.33% Larimar Therapeutics N/A -134.14% -96.00%

Does the media refer more to ALDX or LRMR?

In the previous week, Aldeyra Therapeutics had 6 more articles in the media than Larimar Therapeutics. MarketBeat recorded 7 mentions for Aldeyra Therapeutics and 1 mentions for Larimar Therapeutics. Larimar Therapeutics' average media sentiment score of 0.54 beat Aldeyra Therapeutics' score of 0.16 indicating that Larimar Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aldeyra Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Larimar Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer AVIR or ALDX?

Aldeyra Therapeutics has a consensus target price of $5.50, suggesting a potential upside of 213.39%. Given Aldeyra Therapeutics' higher probable upside, analysts plainly believe Aldeyra Therapeutics is more favorable than Atea Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atea Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Aldeyra Therapeutics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings & valuation, AVIR or ALDX?

Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atea Pharmaceuticals N/A N/A -$158.35M -$2.11 N/A Aldeyra Therapeutics N/A N/A -$33.85M -$0.46 N/A

Is AVIR or ALDX more profitable?

Atea Pharmaceuticals' return on equity of -57.01% beat Aldeyra Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Atea Pharmaceuticals N/A -57.01% -51.49% Aldeyra Therapeutics N/A -57.34% -36.33%

Does the media favor AVIR or ALDX?

In the previous week, Aldeyra Therapeutics had 6 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 7 mentions for Aldeyra Therapeutics and 1 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 1.04 beat Aldeyra Therapeutics' score of 0.16 indicating that Atea Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atea Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aldeyra Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Aldeyra Therapeutics (ALDX) Competitors

$1.76 -0.11 (-5.65%)

As of 01:56 PM Eastern

Compare

ALDX vs. SNDL, CMPX, PBYI, LRMR, and AVIR

Should you buy Aldeyra Therapeutics stock or one of its competitors? MarketBeat compares Aldeyra Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aldeyra Therapeutics include SNDL (SNDL), Compass Therapeutics (CMPX), Puma Biotechnology (PBYI), Larimar Therapeutics (LRMR), and Atea Pharmaceuticals (AVIR). These companies are all part of the "pharmaceutical products" industry.

How does Aldeyra Therapeutics compare to SNDL?

Aldeyra Therapeutics (NASDAQ:ALDX) and SNDL (NASDAQ:SNDL) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, media sentiment, dividends, risk and analyst recommendations.

Aldeyra Therapeutics has a beta of 1.19, indicating that its share price is 19% more volatile than the broader market. Comparatively, SNDL has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market.

Aldeyra Therapeutics has a net margin of 0.00% compared to SNDL's net margin of -1.19%. SNDL's return on equity of -1.02% beat Aldeyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aldeyra Therapeutics	N/A	-57.34%	-36.33%
SNDL	-1.19%	-1.02%	-0.85%

SNDL has higher revenue and earnings than Aldeyra Therapeutics. SNDL is trading at a lower price-to-earnings ratio than Aldeyra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.46	N/A
SNDL	$677.32M	0.55	-$11.29M	-$0.03	N/A

Aldeyra Therapeutics presently has a consensus price target of $5.50, suggesting a potential upside of 213.39%. SNDL has a consensus price target of $5.00, suggesting a potential upside of 243.64%. Given SNDL's higher possible upside, analysts plainly believe SNDL is more favorable than Aldeyra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aldeyra Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
SNDL	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

59.7% of Aldeyra Therapeutics shares are held by institutional investors. 11.8% of Aldeyra Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Aldeyra Therapeutics had 2 more articles in the media than SNDL. MarketBeat recorded 7 mentions for Aldeyra Therapeutics and 5 mentions for SNDL. SNDL's average media sentiment score of 1.06 beat Aldeyra Therapeutics' score of 0.16 indicating that SNDL is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aldeyra Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
SNDL	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

SNDL beats Aldeyra Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Aldeyra Therapeutics compare to Compass Therapeutics?

Compass Therapeutics (NASDAQ:CMPX) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings, valuation and dividends.

Compass Therapeutics' return on equity of -39.75% beat Aldeyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Therapeutics	N/A	-39.75%	-35.29%
Aldeyra Therapeutics	N/A	-57.34%	-36.33%

Compass Therapeutics presently has a consensus target price of $12.91, indicating a potential upside of 510.36%. Aldeyra Therapeutics has a consensus target price of $5.50, indicating a potential upside of 213.39%. Given Compass Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Compass Therapeutics is more favorable than Aldeyra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86
Aldeyra Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Compass Therapeutics has a beta of 0.89, suggesting that its stock price is 11% less volatile than the broader market. Comparatively, Aldeyra Therapeutics has a beta of 1.19, suggesting that its stock price is 19% more volatile than the broader market.

68.4% of Compass Therapeutics shares are owned by institutional investors. Comparatively, 59.7% of Aldeyra Therapeutics shares are owned by institutional investors. 18.7% of Compass Therapeutics shares are owned by company insiders. Comparatively, 11.8% of Aldeyra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Aldeyra Therapeutics had 3 more articles in the media than Compass Therapeutics. MarketBeat recorded 7 mentions for Aldeyra Therapeutics and 4 mentions for Compass Therapeutics. Compass Therapeutics' average media sentiment score of 0.41 beat Aldeyra Therapeutics' score of 0.16 indicating that Compass Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compass Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aldeyra Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aldeyra Therapeutics has lower revenue, but higher earnings than Compass Therapeutics. Compass Therapeutics is trading at a lower price-to-earnings ratio than Aldeyra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Therapeutics	$850K	448.11	-$66.49M	-$0.41	N/A
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.46	N/A

Summary

Compass Therapeutics beats Aldeyra Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Aldeyra Therapeutics compare to Puma Biotechnology?

Puma Biotechnology (NASDAQ:PBYI) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk, analyst recommendations and media sentiment.

61.3% of Puma Biotechnology shares are held by institutional investors. Comparatively, 59.7% of Aldeyra Therapeutics shares are held by institutional investors. 22.2% of Puma Biotechnology shares are held by insiders. Comparatively, 11.8% of Aldeyra Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Puma Biotechnology has higher revenue and earnings than Aldeyra Therapeutics. Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Puma Biotechnology	$228.40M	1.52	$31.11M	$0.48	14.18
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.46	N/A

Puma Biotechnology has a net margin of 10.69% compared to Aldeyra Therapeutics' net margin of 0.00%. Puma Biotechnology's return on equity of 20.30% beat Aldeyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Puma Biotechnology	10.69%	20.30%	12.05%
Aldeyra Therapeutics	N/A	-57.34%	-36.33%

In the previous week, Aldeyra Therapeutics had 6 more articles in the media than Puma Biotechnology. MarketBeat recorded 7 mentions for Aldeyra Therapeutics and 1 mentions for Puma Biotechnology. Puma Biotechnology's average media sentiment score of 0.94 beat Aldeyra Therapeutics' score of 0.16 indicating that Puma Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Puma Biotechnology	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aldeyra Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aldeyra Therapeutics has a consensus price target of $5.50, suggesting a potential upside of 213.39%. Given Aldeyra Therapeutics' higher possible upside, analysts clearly believe Aldeyra Therapeutics is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Puma Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aldeyra Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Puma Biotechnology has a beta of 1.21, meaning that its stock price is 21% more volatile than the broader market. Comparatively, Aldeyra Therapeutics has a beta of 1.19, meaning that its stock price is 19% more volatile than the broader market.

Summary

Puma Biotechnology beats Aldeyra Therapeutics on 11 of the 14 factors compared between the two stocks.

How does Aldeyra Therapeutics compare to Larimar Therapeutics?

Aldeyra Therapeutics (NASDAQ:ALDX) and Larimar Therapeutics (NASDAQ:LRMR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, dividends, valuation, risk, profitability, earnings and analyst recommendations.

Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.46	N/A
Larimar Therapeutics	N/A	N/A	-$165.67M	-$2.06	N/A

Aldeyra Therapeutics' return on equity of -57.34% beat Larimar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aldeyra Therapeutics	N/A	-57.34%	-36.33%
Larimar Therapeutics	N/A	-134.14%	-96.00%

59.7% of Aldeyra Therapeutics shares are owned by institutional investors. Comparatively, 91.9% of Larimar Therapeutics shares are owned by institutional investors. 11.8% of Aldeyra Therapeutics shares are owned by company insiders. Comparatively, 4.5% of Larimar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Aldeyra Therapeutics has a beta of 1.19, meaning that its stock price is 19% more volatile than the broader market. Comparatively, Larimar Therapeutics has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market.

In the previous week, Aldeyra Therapeutics had 6 more articles in the media than Larimar Therapeutics. MarketBeat recorded 7 mentions for Aldeyra Therapeutics and 1 mentions for Larimar Therapeutics. Larimar Therapeutics' average media sentiment score of 0.54 beat Aldeyra Therapeutics' score of 0.16 indicating that Larimar Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aldeyra Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Larimar Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aldeyra Therapeutics presently has a consensus price target of $5.50, suggesting a potential upside of 213.39%. Larimar Therapeutics has a consensus price target of $15.29, suggesting a potential upside of 381.44%. Given Larimar Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Larimar Therapeutics is more favorable than Aldeyra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aldeyra Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.09

Summary

Aldeyra Therapeutics and Larimar Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Aldeyra Therapeutics compare to Atea Pharmaceuticals?

Atea Pharmaceuticals (NASDAQ:AVIR) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

86.7% of Atea Pharmaceuticals shares are owned by institutional investors. Comparatively, 59.7% of Aldeyra Therapeutics shares are owned by institutional investors. 21.6% of Atea Pharmaceuticals shares are owned by company insiders. Comparatively, 11.8% of Aldeyra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.11	N/A
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.46	N/A

Atea Pharmaceuticals has a beta of 0.32, meaning that its stock price is 68% less volatile than the broader market. Comparatively, Aldeyra Therapeutics has a beta of 1.19, meaning that its stock price is 19% more volatile than the broader market.

Atea Pharmaceuticals' return on equity of -57.01% beat Aldeyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atea Pharmaceuticals	N/A	-57.01%	-51.49%
Aldeyra Therapeutics	N/A	-57.34%	-36.33%

In the previous week, Aldeyra Therapeutics had 6 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 7 mentions for Aldeyra Therapeutics and 1 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 1.04 beat Aldeyra Therapeutics' score of 0.16 indicating that Atea Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atea Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aldeyra Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aldeyra Therapeutics has a consensus target price of $5.50, suggesting a potential upside of 213.39%. Given Aldeyra Therapeutics' higher probable upside, analysts plainly believe Aldeyra Therapeutics is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atea Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Aldeyra Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Atea Pharmaceuticals and Aldeyra Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

Get Aldeyra Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALDX vs. The Competition

Export

Metric	Aldeyra Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$105.86M	$2.97B	$6.43B	$12.45B
Dividend Yield	N/A	1.68%	2.69%	5.22%
P/E Ratio	-3.82	18.10	23.85	24.37
Price / Sales	N/A	306.21	522.03	117.40
Price / Cash	N/A	55.72	41.27	57.13
Price / Book	2.37	3.94	10.04	6.75
Net Income	-$33.85M	$75.85M	$3.56B	$337.03M
7 Day Performance	0.29%	-1.56%	-0.82%	0.08%
1 Month Performance	N/A	N/A	N/A	-1.66%
1 Year Performance	-28.95%	23.11%	28.88%	34.01%

Aldeyra Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALDX Aldeyra Therapeutics	3.3148 of 5 stars	$1.76 -5.6%	$5.50 +213.4%	-20.9%	$105.86M	N/A	N/A	10
SNDL SNDL	3.4977 of 5 stars	$1.45 flat	$5.00 +244.8%	+10.2%	$373.23M	$677.32M	N/A	2,751	Positive News
CMPX Compass Therapeutics	2.5089 of 5 stars	$2.07 flat	$13.60 +557.0%	-1.9%	$372.78M	$850K	N/A	20	Analyst Forecast
PBYI Puma Biotechnology	1.2654 of 5 stars	$7.08 flat	N/A	+105.1%	$360.36M	$228.40M	14.75	200	Positive News
LRMR Larimar Therapeutics	2.4993 of 5 stars	$3.45 flat	$16.33 +373.4%	+32.8%	$358.40M	N/A	N/A	30

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALDX) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aldeyra Therapeutics (ALDX) Competitors

ALDX vs. SNDL, CMPX, PBYI, LRMR, and AVIR

How does Aldeyra Therapeutics compare to SNDL?

Summary

How does Aldeyra Therapeutics compare to Compass Therapeutics?

Summary

How does Aldeyra Therapeutics compare to Puma Biotechnology?

Summary

How does Aldeyra Therapeutics compare to Larimar Therapeutics?

Summary

How does Aldeyra Therapeutics compare to Atea Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALDX vs. The Competition

Aldeyra Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aldeyra Therapeutics (ALDX) Competitors

ALDX vs. SNDL, CMPX, PBYI, LRMR, and AVIR

How does Aldeyra Therapeutics compare to SNDL?

Which has more volatility and risk, ALDX or SNDL?

Is ALDX or SNDL more profitable?

Which has preferable earnings & valuation, ALDX or SNDL?

Do analysts recommend ALDX or SNDL?

Do insiders & institutionals have more ownership in ALDX or SNDL?

Does the media refer more to ALDX or SNDL?

Summary

How does Aldeyra Therapeutics compare to Compass Therapeutics?

Is CMPX or ALDX more profitable?

Do analysts prefer CMPX or ALDX?

Which has more risk & volatility, CMPX or ALDX?

Do insiders and institutionals believe in CMPX or ALDX?

Does the media prefer CMPX or ALDX?

Which has preferable valuation & earnings, CMPX or ALDX?

Summary

How does Aldeyra Therapeutics compare to Puma Biotechnology?

Do insiders and institutionals have more ownership in PBYI or ALDX?

Which has better earnings & valuation, PBYI or ALDX?

Is PBYI or ALDX more profitable?

Does the media prefer PBYI or ALDX?

Do analysts recommend PBYI or ALDX?

Which has more risk and volatility, PBYI or ALDX?

Summary

How does Aldeyra Therapeutics compare to Larimar Therapeutics?

Which has higher valuation and earnings, ALDX or LRMR?

Is ALDX or LRMR more profitable?

Do insiders & institutionals hold more shares of ALDX or LRMR?

Which has more volatility & risk, ALDX or LRMR?

Does the media refer more to ALDX or LRMR?

Do analysts rate ALDX or LRMR?

Summary

How does Aldeyra Therapeutics compare to Atea Pharmaceuticals?

Do institutionals & insiders have more ownership in AVIR or ALDX?

Which has stronger earnings & valuation, AVIR or ALDX?

Which has more volatility & risk, AVIR or ALDX?

Is AVIR or ALDX more profitable?

Does the media favor AVIR or ALDX?

Do analysts prefer AVIR or ALDX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALDX vs. The Competition

Aldeyra Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools